Giant Malignant Meningioma Penetrates the Skull.
Journal
The Journal of craniofacial surgery
ISSN: 1536-3732
Titre abrégé: J Craniofac Surg
Pays: United States
ID NLM: 9010410
Informations de publication
Date de publication:
01 Sep 2023
01 Sep 2023
Historique:
received:
24
03
2023
accepted:
15
04
2023
medline:
31
8
2023
pubmed:
20
6
2023
entrez:
19
6
2023
Statut:
ppublish
Résumé
Meningioma is a primary tumor of the central nervous system, most commonly found in the middle-aged and elderly. Most meningiomas are benign, whereas malignant meningiomas account for only 1% of all meningiomas. Meningiomas usually grow slowly, and patients often have headaches and epilepsy as the first symptoms. According to the location of the tumor, there can also be vision, visual field, olfactory, hearing impairment, and so on. Surgery is the main treatment. A case of giant malignant meningioma penetrating the skull is reported. The patient was a 67-year-old male with a left parietal scalp mass about 1 year ago, which gradually enlarged to the size of 6×6 cm and had no other symptoms. Imaging examination showed that the tumor eroded the skull, and the density was uneven. After surgical resection (Simpson grade I), poorly differentiated meningioma (World Health Organization Grade Ⅲ) was returned pathologically. After operation, the patient recovered well.
Identifiants
pubmed: 37336497
doi: 10.1097/SCS.0000000000009436
pii: 00001665-202309000-00085
doi:
Types de publication
Case Reports
Journal Article
Langues
eng
Pagination
e584-e586Informations de copyright
Copyright © 2023 by Mutaz B. Habal, MD.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest.
Références
Louis DN, Perry A, Wesseling P, et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro-oncology 2021;23:1231–1251
Di Nunno V, Giannini C, Asioli S, et al. Diagnostic and therapeutic strategy in anaplastic (malignant) meningioma, CNS WHO Grade 3. Cancers (Basel) 2022;14:4689
Wiemels J, Wrensch M, Claus EB. Epidemiology and etiology of meningioma. J Neurooncol 2010;99:307–314
Rockhill J, Mrugala M, Chamberlain MC. Intracranial meningiomas: an overview of diagnosis and treatment. Neurosurg Focus 2007;23:E1
Zeng L, Liang P, Jiao J, et al. Will an asymptomatic meningioma grow or not grow? A meta-analysis. J Neurol Surg A Cent Eur Neurosurg 2015;76:341–347
Huang RY, Bi WL, Weller M, et al. Proposed response assessment and endpoints for meningioma clinical trials: report from the Response Assessment in Neuro-Oncology Working Group. Neurooncology 2019;21:26–36
O’Leary S, Adams WM, Parrish RW, et al. Atypical imaging appearances of intracranial meningiomas. Clinical Radiol 2007;62:10–17
Simpson D. The recurrence of intracranial meningiomas after surgical treatment. J Neurol Neurosurg Psychiatry 1957;20:22–39
Mirimanoff RO, Dosoretz DE, Linggood RM, et al. Meningioma: analysis of recurrence and progression following neurosurgical resection. J Neurosurg 1985;62:18–24
Jääskeläinen J. Seemingly complete removal of histologically benign intracranial meningioma: late recurrence rate and factors predicting recurrence in 657 patients. A multivariate analysis. Surg Neuro 1986;26:461–469
Hug EB, Devries A, Thornton AF, et al. Management of atypical and malignant meningiomas: role of high-dose, 3D-conformal radiation therapy. J Neurooncol 2000;48:151–160
Maggio I, Franceschi E, Tosoni A, et al. Meningioma: not always a benign tumor. A review of advances in the treatment of meningiomas. CNS Oncol 2021;10:Cns72